FDA Requires New GLP-1 Drug Warnings About a Potential Risk of Rare but Permanent Vision Loss

type 2 diabetes and in those who were overweight or had obesity. The FDA recognized that the study had limitations, yet it raised enough concern to justify a deeper evaluation across the entire drug class.

Three GLP-1 medication products — Wegovy injector pens, Ozempic, and Victoza — are arranged against a plain white background.

To gain a broader view, the agency carried out a meta-analysis of 126 randomized controlled trials covering GLP-1 RA development programs. This large dataset included more than 134,000 patients and close to 289,000 person-years of exposure. Within that extensive pool, the FDA identified 15 probable NAION events. Ten occurred in patients treated with

Leave a Reply

Your email address will not be published. Required fields are marked *